TAB1 Antibody
| Code | Size | Price |
|---|
| PSI-3387-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-3387-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
TAB1 Antibody: 3'-Tab1, MAP3K7IP1, TGF-beta-activated kinase 1 and MAP3K7-binding protein 1, Mitogen-activated protein kinase kinase kinase 7-interacting protein 1, TAK1-binding protein 1
Application Note:
TAB1 antibody can be used for the detection of TAB1 by Western blot at 0.5 to 2 μg/mL. Antibody can also be used for immunocytochemistry starting at 1 μg/mL. For immunofluorescence start at 2 μg/mL.
Antibody validated: Western Blot in mouse samples; Immunocytochemistry in human samples and Immunofluorescence in mouse samples. All other applications and species not yet tested.
Antibody validated: Western Blot in mouse samples; Immunocytochemistry in human samples and Immunofluorescence in mouse samples. All other applications and species not yet tested.
Background:
TAB1 Antibody: TAB1 was identified as a regulator of the MAP kinase kinase kinase TAK1/MAP3K7, which is known to mediate various intracellular signaling pathways, such as those induced by TGF-beta and members of the Toll-IL-1R (TIR) superfamily, thus acting as an intermediate in both proliferative and innate and adaptive immune responses. This protein, together with either TAB2 or TAB3, activates TAK1 kinase in response to upstream signals. It has been shown that the C-terminal portion of TAB1 is sufficient for binding and activation of TAK1, while a portion of the N-terminus acts as a dominant-negative inhibitor of TGF-beta, demonstrating how this protein can function as a mediator between TGF-beta receptors and TAK1.
Background References:
- Shibuya H, Yamaguchi K, Shirakabe K, et al. TAB1: an activator of the TAK1 MAPKKK in TGF-β signal transduction. Science 1996; 272:1179-82.
- Irie T, Muta T, and Takeshige K. TAK1 mediates an activation signal from toll-like receptor(s) to nuclear factor-κB in lipopolysaccharide-stimulated macrophages. FEBS Lett. 2000; 467:160-4.
- Akira S and Takeda K. Toll-like receptor Signalling. Nat. Rev. Immunol. 2004; 4:499-511.
- Jiang Z, Ninomiya-Tsuji J, Qian Y, et al. Interleukin-1 (IL-1) receptor-associated kinase-dependent IL-1-induced signaling complexes phosphorylate TAK1 and TAB2 at the plasma membrane and activate TAK1 in the cytosol. Mol. Cell Biol. 2002; 22:7158-67.
Buffer:
TAB1 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
TAB1 antibody was raised against a synthetic peptide corresponding to 13 amino acids in the center of human TAB1.
The immunogen is located within amino acids 220 - 270 of TAB1.
The immunogen is located within amino acids 220 - 270 of TAB1.
NCBI Gene ID #:
10454
NCBI Official Name:
TGF-beta activated kinase 1 (MAP3K7) binding protein 1
NCBI Official Symbol:
TAB1
NCBI Organism:
Homo sapiens
Physical State:
Liquid
Protein Accession #:
NP_006107
Protein GI Number:
5174703
Purification:
TAB1 Antibody is affinity chromatography purified via peptide column.
Research Area:
Innate Immunity
Swissprot #:
Q15750
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | TAB1 Peptide | PSI-3387P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|